Amgen to partner with Array BioPharma on autoimmune disorder therapies

Amgen has announced a new partnership with Array BioPharma that will aim to create innovative new therapies for the treatment of autoimmune disorders.

The partnership will focus on the discovery and development of novel drugs for autoimmune disease, with undisclosed targets and lead inhibitors discovered through a proprietary Array platform that leverages its expertise in chemistry and early lead development.

Both companies will collaborate on preclinical development, with Array leading the medicinal chemistry work, while Amgen takes responsibility for the clinical development and commercialisation phases.

In exchange for exclusive rights to Array's preclinical programme, Amgen will make a number of upfront and milestone payments to its partner, as well as paying royalties on sales of resulting therapies.

Dr Flavius Martin, vice-president of research, inflammation and oncology at Amgen, said: "We are pleased to enter this collaboration with Array that builds on our continued focus in inflammation, one of Amgen's key strategic areas of interest."

It is hoped that this will result in the development of a new drug that can address a significant unmet medical need for patients with inflammatory disease.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.